No­vavax sells Czech fa­cil­i­ty to No­vo Nordisk for $200M to cut costs

No­vo Nordisk is buy­ing a vac­cine man­u­fac­tur­ing fac­to­ry from No­vavax for $200 mil­lion to ex­pand pro­duc­tion of its cur­rent and fu­ture mam­malian-based prod­ucts, a spokesper­son …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER